Flow cytometry effectively detects CTCs in melanoma patients, offering a rapid, cost-effective alternative to molecular biology. CTCs are present across all melanoma stages, with a significant ...

Flow cytometry offers practical advantages for real-time monitoring of CAR T cell expansion, persistence, and toxicity risk in aggressive large B-cell lymphoma patients. Early CAR T cell expansion is ...

MRD refers to cancer cells remaining post-treatment, undetectable by standard imaging, indicating potential recurrence risk. MRD testing methods include flow cytometry and genetic tests, offering ...

Over the past decade, flow cytometry has undergone transformative advancements, notably with the adoption of spectral flow cytometry and the emergence of next-generation imaging cytometers. These ...

Not all patients respond well to chimeric antigen receptor (CAR) T cell therapies, which reprogram a patient’s own immune cells to recognize and attack cancer. A way to optimize these treatments is to ...

Researchers investigating ways to reduce exhaustion in cancer-fighting T-cells found that the Golgi apparatus can be used as a simple marker -- more Golgi means a more robust cell. The Golgi apparatus ...